HLA-G is expressed on fetal derived placental cells. Exon one encodes the leader peptide, exons 2 and 3 encode the ?1 and ?2 domain, which both bind the peptide, exon 4 encodes the ?3 domain, exon 5 encodes the transmembrane region, and exon 6 encodes the cytoplasmic tail.
| Inventor | Institute |
|---|---|
| Daniel Geraghty | Fred Hutchinson Cancer Center |
| Cat. #: | 161665 |
|---|---|
| Tool sub type: | Primary antibody |
| Cancer types: | Skin cancer, Breast cancer |
| Research Fields: | Developmental biology;Immunology |
| Application: | Immunohistochemistry (Frozen), Immunocytochemistry, Flow Cytometry, ELISA, Immunoprecipitation. No western |
| Target: | Membrane-bound form of HLA-G (full-length HLA-G1) |
| Reactivity: | Human |
| Clone: | 01G |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | lshitani et al.2003. Journal of lmmunology. 171(3):1376-84. PMID: 12874228 |
| Product description: | HLA-G has long been assumed a major factor in immune accommodation because of its localized expression and low levels of allelic polymorphism. This MoAb were developed to examine the role of all three nonclassical class I Ags in the maternal immune response during pregnancy. 0lG was developed to react specifically with the membrane form of HLA-G. |
|---|---|
| Isotype: | IgG1 |
| Molecular weight: | The heavy chain is approximately 45 kDa |
| Target background: | HLA-G are expressed in the placenta, a membrane form and a soluble form, the latter containing an altered carboxyl terminu. HLA-G belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (?2 microglobulin). The heavy chain is anchored in the membrane. |
|---|
| Storage buffer: | PBS, pH 7.4 |
|---|---|
| Storage conditions: | 4° C do not freeze |
| Shipping conditions: | Dry ice |
| References: |
lshitani et al.2003.Journal of lmmunology. 171(3):1376-84.PMID: 12874228 Lee et al.1995. Immunity.(5):591-600.PMID: 7584149 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.